Chardan Capital initiated coverage on shares of Reviva Pharmaceuticals (NASDAQ:RVPH – Free Report) in a research report sent to investors on Monday, MarketBeat reports. Citigroup reiterated a “buy” rating on shares of Reviva Pharmaceuticals in a report on Friday, August 15th. Get Reviva Pharmaceuticals alerts:View Our Latest Research Report on Reviva PharmaceuticalsReviva Pharmaceuticals Stock Up 4.5%Shares of Reviva Pharmaceuticals stock opened at $0.31 on Monday. Reviva Pharmaceuticals has a fifty-two week low of $0.25 and a fifty-two week high of $4.28. Featured StoriesReceive News & Ratings for Reviva Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reviva Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.